Application of lentinan in preparing drug for inhibiting activity of alpha-glucosaccharase

A technology of glucosidase and lentinan, which is applied in the directions of drug combination, organic active ingredients, pharmaceutical formulations, etc., can solve the problem that α-glucosidase active drugs have not been reported, and achieve the effect of preventing diabetes and reducing postprandial blood sugar.

Inactive Publication Date: 2019-07-09
LIAONING UNIVERSITY
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, the application of lentinan in the preparation of drugs inhibiting α-glucosidase activity has not been reported yet.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of lentinan in preparing drug for inhibiting activity of alpha-glucosaccharase
  • Application of lentinan in preparing drug for inhibiting activity of alpha-glucosaccharase
  • Application of lentinan in preparing drug for inhibiting activity of alpha-glucosaccharase

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Example 1 The inhibitory effect of lentinan on the activity of α-glucosidase

[0022] Take 40 μL α-glucosidase (final concentration is 4 μM) and 40 μL different concentrations of lentinan solution (final concentration is 0.3, 0.6, 0.9, 1.2, 1.5, 1.8, 2.1, 2.4, 2.7 mM), at 37 ° C, pH = Incubate in the phosphate buffer solution of 6.8 for 10 minutes, then add 40 μL p-nitrophenyl-α-D-glucopyranoside (final concentration is 8 mM), put it in a constant temperature shaker at 37°C for 60 minutes, and add 120 μL 0.2mol·L -1 Sodium carbonate solution, its absorbance was measured at 405nm. At the same time, the inhibitor test group, the inhibitor control group, the enzyme activity test group and the enzyme activity control group were made, as shown in Table 1. Each experiment was repeated more than 3 times. Calculate α-glucosidase inhibitory percentage=[1-(A by the following formula 抑制剂实验组 -A 抑制剂对照组 ) / (A 酶活实验组 -A 酶活对照组 )] × 100%. Depend on figure 1 It can be seen that wi...

Embodiment 2

[0026] Example 2 Judgment of the inhibition type of lentinan to α-glucosidase

[0027] Take 40 μL of different concentrations of lentinan (final concentrations: 0, 0.9, 1.5, and 2.1 mM), add 40 μL of α-glucosidase (final concentrations: 1, 2, and 4 μM) respectively, and put them in a constant temperature shaker at 37°C for 10 minutes. Then add 40 μL of p-nitrophenyl-α-D-glucopyranoside (final concentration: 8 mM), react at 37°C for 60 min, and add 120 μL after the reaction to a concentration of 0.2 mol L -1 Sodium carbonate solution, its absorbance was measured at 405nm. Linear fitting was carried out with different enzyme concentrations and reaction speeds. As the concentration of different lentinan increased, the slope of the line increased and all lines passed the origin, and the type of reversible inhibition could be judged. Depend on figure 2 It can be seen that the straight line a is the blank group (the final concentration of lentinan is 0); the straight lines b-d ar...

Embodiment 3

[0028] Embodiment 3 Lentinan is to the Lineweaver-Burk curve of α-glucosidase inhibitory effect

[0029] Take 40 μL of different concentrations of lentinan (final concentration: 0, 0.9, 1.5, 2.1 mM), add 40 μL α-glucosidase (final concentration: 4 μM) respectively, put them in a constant temperature shaker at 37°C for 10 minutes, and then put them in 40 μL p-nitrophenyl-α-D-glucopyranoside (final concentration: 2, 4, 8 mM), react at 37°C for 60 min, after the reaction, add 120 μL with a concentration of 0.2mol L -1 Sodium carbonate solution, its absorbance was measured at 405nm. Using Lineweaver-Burk's double reciprocal plot, if you get a set of straight lines with different slopes and intersecting on the Y axis, it is competitive inhibition; if you get a set of straight lines with different slopes and intersecting on the X axis, it is non-competitive inhibition ; If you get a set of straight lines with different slopes that intersect in the second or third quadrant, it is mi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of lentinan in preparing a drug for inhibiting activity of alpha-glucosaccharase. The lentinan can achieve the purposes of reducing postprandial blood sugar and preventing diabetes by inhibiting the activity of the alpha-glucosaccharase. The invention aims to research and develop a health care product for reducing the blood sugar with a good curative effect andsmall side effects to effectively control the activity of the alpha-glucosaccharase, which can reduce the postprandial blood sugar and prevent the occurrence of the diabetes. A new idea is provided for studying the lentinan as the health care product for reducing the postprandial blood sugar and preventing the occurrence of the diabetes.

Description

technical field [0001] The invention relates to the application of lentinan in the preparation of drugs for inhibiting alpha-glucosidase activity, and belongs to the technical field of research and development of health food. Background technique [0002] Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease characterized by disorders of carbohydrate and fat metabolism. It is estimated that the global incidence rate will reach 10.4% of the world's population in 2040, becoming one of the most concerned health problems in developing countries. T2DM can cause cardiovascular and cerebrovascular diseases such as hypertension and hyperlipidemia, as well as various complications such as kidney, retina and neuropathy, which seriously endanger health and life. Family and society bring heavy economic and spiritual burden. The goal of T2DM treatment is to control blood sugar to reduce long-term complications and reduce mortality. T2DM mainly manifests as defects in insulin ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/715A61K45/06A61P3/10
CPCA61K31/715A61K45/06A61P3/10
Inventor 曹向宇孔宇驰繆静宜何勇林李其久牟藤
Owner LIAONING UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products